Sequent Scientific posts 13% revenue growth amid merger progress

Sequent Scientific reported strong Q1 FY26 performance with total revenue reaching INR4,414 million, up 13.1% year-on-year. Formulation revenue grew 13% to INR3,379 million while API revenue increased 14% to INR1,054 million.

Adjusted EBITDA rose 24.7% to INR602 million, expanding margins to 13.6%. Profit after tax soared 93.7% to INR176 million.

The strategic merger with Viyash Group is progressing, with competition commission and stock exchange approvals secured. A shareholders' and creditors' meeting is scheduled for August 30, 2025, keeping the merger on track for completion within 12 to 15 months.

Combined entities saw 8.7% revenue growth and 21% EBITDA rise for the quarter.